Leading Companies Enhancing Their Presence in the Omics-Based Clinical Trials Market

The omics-based clinical trials sector is rapidly evolving, driven by advancements in precision medicine and data analytics. As healthcare embraces these innovative approaches, the market is poised to experience significant expansion in the near future. Here, we explore the market's growth trajectory, key players, emerging trends, and the main segments shaping its development.

Strong Forecasted Growth in the Omics-Based Clinical Trials Market
The market for omics-based clinical trials is projected to expand substantially, reaching a valuation of $47.78 billion by 2030. This growth represents a compound annual growth rate (CAGR) of 8.5%. Several factors support this upward trend, including the rising adoption of precision medicine, increased investment in data-driven clinical trials, the expansion of AI-powered patient recruitment methods, growing regulatory support for omics-based endpoints, and a higher demand for more efficient clinical trial results. Key trends anticipated during this period involve wider use of biomarker-driven trial designs, multi-omics patient stratification approaches, integration of real-world evidence analytics, growth in precision oncology trials, and a stronger emphasis on optimizing trials using data-centric approaches.

Download a free report of the omics-based clinical trials market report:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Top Companies Leading the Omics-Based Clinical Trials Market
The competitive landscape of the omics-based clinical trials market features prominent companies such as Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.

A Noteworthy Acquisition Enhancing Multiomics Capabilities in 2025
In June 2025, Bruker Corporation, a US-based manufacturer specializing in scientific instruments and diagnostic testing, acquired Biocrates Life Sciences AG, an Austria-based biotechnology firm, for an undisclosed sum. This strategic move aims to bolster Bruker's multiomics solutions by integrating Biocrates' mass spectrometry-based metabolomics technology. The goal is to provide standardized, reproducible, and comprehensive quantitative workflows tailored for life sciences and clinical research, thus enhancing the capabilities available in omics-based clinical trials.

View the full omics-based clinical trials market report:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Innovative Developments Shaping the Trocar Market and Surgical Procedures
Companies in the trocar market are concentrating on creating advanced, minimally invasive surgical instruments to address the growing demand for safer laparoscopic procedures. These next-generation trocars emphasize reduced surgical trauma, faster recovery times, and improved efficiency in operating rooms. Designed with optimized cannula geometry, built-in safety features, and ergonomic designs, these trocars allow surgeons precise access to body cavities while minimizing tissue damage-improvements compared to traditional rigid and manually inserted designs with higher complication risks. For example, in December 2023, Xpan Inc., a US medical device company, received FDA 510(k) clearance and completed initial human clinical trials for its new trocar system. This system features a precision-engineered cannula and obturator with integrated safety elements that enable controlled penetration and reduce port-site trauma. Its unique benefits include lower insertion force, safety shields, ergonomic handles, and compatibility with a wide range of laparoscopic tools. Applications cover general surgery, gynecology, urology, and bariatrics, offering advantages such as fewer complications, enhanced procedural efficiency, and improved patient recovery.

Key Segments Defining the Omics-Based Clinical Trials Market
This market is categorized into several essential segments:
1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Hospitals and Diagnostic Laboratories

Detailed subsegments include:
- Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
- Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
- Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
- Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

This diverse segmentation allows for a comprehensive understanding of the market's components and their respective roles in driving growth.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.